Alto Neuroscience
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
650 Castro St Ste 450, Mountain View, Ca...Phone Number
(650) 200-0412Website
www.altoneuroscience.comRevenue
$14.2 MillionStock Symbol
ANROIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Alto Neuroscience
Alto Neuroscience develops biology-driven psychiatric medicines using a precision-medicine approach. The companys platform measures brain biomarkers like EEG data, neurocognitive and wearable metrics to match patients with treatments most likely to benefit them. Their clinical-stage pipeline targets neuropsychiatric conditions such as major depressive disorder, bipolar depression, and schizophrenia. They aim to improve outcomes and speed recovery by replacing trial-and-error prescriptions with data-backed, personalized therapies.Explore more
Alto Neuroscience Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Alto Neuroscience your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Alto Neuroscience
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Alto Neuroscience had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check out if Alto Neuroscience is spiking on competitors!
Alto Neuroscience, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Alto Neuroscience has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Alto Neuroscience launches new products
Funding: Get notified immidiatlly once Alto Neuroscience has new funding data
Earning: See what the market has to say on Alto Neuroscience recently announced quarterly report
Recommended Actions
Find VP level buyers at Alto Neuroscience
Find more new buyers
Compare Similar Companies to Alto Neuroscience
Compare insights from companies similar to Alto Neuroscience, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Alto Neuroscience is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Alto Neuroscience is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Alto Neuroscience.
Alto Neuroscience financials insights
Gather financial insights about Alto Neuroscience, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Angel/Seed
$8M
2021
Series A
$32M
2023
Series B
$60M
Series C
$45M
2025
Stock/Share Issuance
$50M
Alto Neuroscience Tech Stack
A closer look at the technologies used by Alto Neuroscience
See more technologies
Most Recent Scoops
Person-Based
Lawsuits, Legal Affairs
Person-Based
Medical Research, Pharmaceuticals
Person-Based
Medical Research
Open Position
Open Position
Alto Neuroscience News & Media
NYSE Content Update: Alto Neuroscience Raises $120 Million to Fund Development of ALTO-207
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, March 23, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before...Alto Neuroscience, Inc. Class Action Notice: ANRO Investors with Large Losses Should Contact Robbins LLP for Information About Leading the Securities Lawsuit
SAN DIEGO, Sept. 19, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired (a) Alto Neuroscience, Inc. (NYSE: ANRO) common stock pursuant and/or traceable to the Offering Documents issued in...ANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, Sept. 18, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE: ANRO) for violations of the federal securities...ALTO NEUROSCIENCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Alto Neuroscience, Inc. (ANRO) and Encourages Investors to Contact the Firm
Alto allegedly overstated ALTO-100’s prospects; after trial failure revealed in Oct 2024, stock fell nearly 70% to $4.36 per share.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Alto Neuroscience
Sign Up For FreeTo access detailed company insights
Alto Neuroscience develops biology-driven psychiatric medicines using a precision-medicine approach. The companys platform measures brain biomarkers like EEG data, neurocognitive and wearable metrics to match patients with treatments most likely to benefit them. Their clinical-stage pipeline targets neuropsychiatric conditions such as major depress... Read More
